T1D-CATCH: Type 1 Diabetes- Collaboration Around Technology Using Community Health Workers

Sponsor
Albert Einstein College of Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05211869
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
130
1
2
29
4.5

Study Details

Study Description

Brief Summary

The objective of this study is to test the early effects and implementation of an enhanced community health worker (CHW) model (T1D-CATCH) that encourages and supports diabetes technology use in young adults from underrepresented minority groups (YA-URMs) with type 1 diabetes (T1D). The investigators will conduct a 6-month randomized controlled trial in which YA-URMs will be randomized toT1D-CATCH or usual care. The investigators will recruit from endocrinology and primary care practices in a large safety-net health system in the Bronx, New York. Our specific aims are to 1) evaluate T1D-CATCH effects on technology initiation and continued use over 6 months and 2) evaluate T1D-CATCH implementation using Proctor's Taxonomy of Implementation Outcomes: feasibility, adoption, fidelity, and cost.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: T1D-CATCH
N/A

Detailed Description

The study will involve a 6-month randomized control trial of usual care versus T1D-CATCH, an intervention that enhances core community health worker (CHW) service roles to support increased use of T1D technology in young adults (underrepresented minorities)(YA_URM's). Participants will be recruited from primary and specialty care practices at Montefiore Medical Center in the Bronx, NY, which is a large safety-net hospital system in one of the poorest counties in the U.S. Two young adult-aged CHWs from the Montefiore CHW program will be trained extensively per our Supporting Emerging Adults with Diabetes (SEAD) program manuals. For YA-URMs, CHWs will conduct hands-on diabetes technology education, goal-setting, peer support, and social service linkage. CHWs will also help shift insurance approval tasks away from busy providers and better align patient-provider priorities through close communication between the YA-URM and provider. Group sessions will be optional and will follow the YA-centric education curriculum developed in Dr. Agarwal's Supporting Emerging Adults with Diabetes (SEAD) program.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
6-month randomized controlled trial in which YA-URMs will be randomized to T1D-CATCH or usual care6-month randomized controlled trial in which YA-URMs will be randomized to T1D-CATCH or usual care
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
Participants will be randomized after enrollment into the study using REDCap. Study staff will notify CHWs of participant assignment to the intervention arm based on REDCap. Investigators, except the PI, and outcome assessors will remain blinded to arm assignment. The PI will not be able to be blinded because they will be required to do supervision and close oversight of the CHWs.
Primary Purpose:
Health Services Research
Official Title:
Type 1 Diabetes- Collaboration Around Technology Using Community Health Workers
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: T1D-CATCH

The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, goal-setting, peer support, and social needs management. Over the 6-month study period, session frequency will involve weekly individual sessions during Month 1 (4 sessions - month 1), bi-weekly individual sessions during Months 2-3 (4 sessions - months 2-3), monthly individual sessions during Months 4-6 (3 sessions - months 4-6), and an optional monthly CHW-led peer group support session. Total amount of sessions equal 11 individual CHW sessions and 6 potential group sessions over the 6-month study period. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institution COVID-19 rules.

Behavioral: T1D-CATCH
As defined by the CDC, a CHW is "a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities". CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities. CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology.

No Intervention: Usual Care Control Condition

Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.

Outcome Measures

Primary Outcome Measures

  1. Technology Use [3 month mark]

    Technology use tracked using EMR prescriptions, self-reporting, CHW records, and device platforms and will be measured as a binary variable (yes/no), days of wear (% use)

  2. Technology Use [6 month mark]

    Technology use tracked using EMR prescriptions, self-reporting, CHW records, and device platforms and will be measured as a binary variable (yes/no), days of wear (% use)

Secondary Outcome Measures

  1. YA-URM Autonomy/ Competence, Social Support [Baseline]

    Measured using the Healthcare Self-Determination survey

  2. YA-URM Autonomy/ Competence, Social Support [3 month mark]

    Measured using the Healthcare Self-Determination survey

  3. YA-URM Autonomy/ Competence, Social Support [6 month mark]

    Measured using the Healthcare Self-Determination survey

  4. Hemoglobin A1c [Baseline]

    Obtained by POC (in clinic) or laboratory (DCA Vantage)

  5. Hemoglobin A1c [3 month mark]

    Obtained by POC (in clinic) or laboratory (DCA Vantage)

  6. Hemoglobin A1c [6 month mark]

    Obtained by POC (in clinic) or laboratory (DCA Vantage)

  7. Quality of Life (Diabetes Distress) [Baseline]

    Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

  8. Quality of Life (Diabetes Distress) [Baseline]

    Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. Total scores of 40 and above: severe diabetes distress Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.

  9. Quality of Life (Diabetes Distress) [Baseline]

    Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

  10. Quality of Life (Diabetes Distress) [Baseline]

    Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.

  11. Quality of Life (Diabetes Distress) [3 month follow-up]

    Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

  12. Quality of Life (Diabetes Distress) [3 month follow-up]

    Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. Total scores of 40 and above: severe diabetes distress Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.

  13. Quality of Life (Diabetes Distress) [3 month follow-up]

    Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

  14. Quality of Life (Diabetes Distress) [3 month follow-up]

    Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.

  15. Quality of Life (Diabetes Distress [6 month follow-up]

    Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

  16. Quality of Life (Diabetes Distress) [6 month follow-up]

    Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. Total scores of 40 and above: severe diabetes distress Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.

  17. Quality of life (Diabetes Distress) [6 month follow-up]

    Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

  18. Quality of Life (Diabetes Distress) [6 month follow-up]

    Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.

Other Outcome Measures

  1. Feasibility Check [6 months (post-intervention)]

    Post-intervention interviews examining intervention content, complexity, comfort, delivery, and credibility

  2. Adoption [6 months (post-intervention)]

    Measured by recruitment logs

  3. Adoption [6 months (post-intervention)]

    Measured by electronic medical records (EMR)

  4. Adoption [6 months (post-intervention)]

    Measured by young adult participant consent rates

  5. Adoption [6 months (post-intervention)]

    Measured by percentage of provider opt-in

  6. Adoption [6 months (post-intervention)]

    Measured by CHW communications

  7. Fidelity [Baseline]

    Measured by the community health worker (CHW) dashboard

  8. Fidelity [Baseline]

    Measured by session recordings

  9. Fidelity [Baseline]

    Measured by electronic medical records (EMR) to analyze session attendance

  10. Fidelity [Baseline]

    Measured by content delivery

  11. Fidelity [Baseline]

    Measured by insurance tasks

  12. Fidelity [3 month mark]

    Measured by community health workers (CHW) dashboard

  13. Fidelity [3 month mark]

    Measured by CHW session recordings

  14. Fidelity [3 month mark]

    Measured by EMR to analyze session attendance

  15. Fidelity [3 month mark]

    Measured by content delivery

  16. Fidelity [3 month mark]

    Measured by insurance tasks

  17. Fidelity [6 month mark]

    Measured by CHW dashboard

  18. Fidelity [6 month mark]

    Measured by CHW session recordings

  19. Fidelity [6 month mark]

    Measured by EMR to analyze session attendance

  20. Fidelity [6 month mark]

    Measured by content delivery

  21. Fidelity [6 month mark]

    Measured by insurance tasks

  22. Cost [6 months (post-intervention)]

    Measured by time sheets, receipts, and budget to analyze CHW salary/benefits

  23. Cost [6 months (post-intervention)]

    Measured by time sheets, receipts, and budget to analyze CHW equipment

  24. Cost [6 months (post-intervention)]

    Measured by time sheets, receipts, and budget to analyze CHW consumables

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 30 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • T1D duration ≥6 months

  • 18-30 years old

  • Self-identified URM status: non-Hispanic Black or Hispanic

  • English- or Spanish-speaking

  • Not currently on diabetes technology (includes never offered, discontinued, or previously refused technology)

Exclusion Criteria:
  • Developmental or sensory disability interfering with study participation

  • Current pregnancy

  • Participation in another behavioral or technology intervention study in the past 6 months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Albert Einstein College of Medicine Bronx New York United States 10461

Sponsors and Collaborators

  • Albert Einstein College of Medicine
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

  • Principal Investigator: Shivani Agarwal, MD, MPH, Albert Einstein College of Medicine

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Albert Einstein College of Medicine
ClinicalTrials.gov Identifier:
NCT05211869
Other Study ID Numbers:
  • 2021-13714
  • R01DK132302
First Posted:
Jan 27, 2022
Last Update Posted:
Aug 9, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 9, 2022